HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PHR
Phreesia, Inc.
PHR's fundamentals are strong: its operating margin went from −5.8% to 2.5% and revenue grew 13%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PHR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Healthy |
PHR's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $12.62 | — |
| Cheap | 59x | $10.60 | -16% |
| Fair | 68x | $12.27 | -2.8% |
| Current | 70x | $12.62 | — |
| Expensive | 215x | $38.67 | +206% |
Historical ranges are pointers, not guarantees.
PHR's PE is 70x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PHR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect PHR's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.62 | +245% |
| Q3 2026 | $0.18 | +$0.60 |
| Q2 2026 | $0.16 | +$0.90 |
| Q1 2026 | $0.04 | +$1.06 |
| Q4 2025 | -$0.10 | +$1.36 |
| Q3 2025 | -$0.42 | +$1.37 |
| Q2 2025 | -$0.74 | +$1.42 |
| Q1 2025 | -$1.02 | +$1.49 |
| Q4 2024 | -$1.46 | +$1.22 |
PHR has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PHR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $129.5M | +10% |
| Q2 2026 | $130.9M | +13% |
| Q1 2026 | $127.1M | +16% |
| Q4 2025 | $120.3M | +13% |
| Q3 2025 | $117.3M | +15% |
| Q2 2025 | $115.9M | +15% |
| Q1 2025 | $109.7M | +15% |
| Q4 2024 | $106.8M | +17% |
PHR's revenue has grown year over year every quarter since late 2020: $129M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.9% | +7.2 points |
| Q2 2026 | 5.2% | +8 points |
| Q1 2026 | -4.4% | +2.6 points |
| Q4 2025 | 3.1% | +16 points |
| Q3 2025 | -1.3% | +16 points |
| Q2 2025 | -2.8% | +16 points |
| Q1 2025 | -6.9% | +24 points |
| Q4 2024 | -13% | +22 points |
PHR has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
PHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $17.8M | +36% |
| Q2 2026 | $19.6M | +73% |
| Q1 2026 | $31.1M | +131% |
| Q4 2025 | $12.2M | +136% |
| Q3 2025 | $13.1M | +97% |
| Q2 2025 | $11.3M | +$12.9M |
| Q1 2025 | $13.5M | +$19M |
| Q4 2024 | $5.2M | +$12.7M |
PHR has the edge over HIMS on cash flow, with more consistent year-over-year improvement.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PHR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +423K shares |
| 1 year | +1.3% | +778K shares |
| 3 years | +16% | +8.7M shares |
| 5 years | +24% | +11.9M shares |
| Available history | +75% | +26.7M shares |
PHR has 62M diluted shares, up 1.3% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | 1.1x | Healthy |
| Q4 2025 | -4.9x | Net Cash |
| Q3 2025 | -44.5x | Net Cash |
PHR has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.4 | Neutral |
| Stochastic | 80.7 | Overbought |
PHR's weekly RSI is 57 (neutral) and its Stochastic is 81 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PHR PE vs Healthcare Sector
| Metric | PHR | Sector median | Relative |
|---|---|---|---|
| PE | 70x | 26x | 171% above |
| PE % | 56 | 29 | 27 pts above |
PHR is trading at 70x earnings, a 171% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.5 | 9.4% above |
| 20 week MA | $11.3 | 12% above |
| 50 week MA | $11.8 | 6.8% above |
| 100 week MA | $18.7 | 33% below |
| 200 week MA | $21.9 | 42% below |
PHR has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.4 | $57.3 | +117% |
| 2021 | $57.3 | $44.2 | -23% |
| 2022 | $44.2 | $33.5 | -24% |
| 2023 | $33.5 | $23.2 | -31% |
| 2024 | $23.2 | $25.8 | +11% |
| 2025 | $25.8 | $17.0 | -34% |
| 2026 YTD | $17.0 | $12.6 | -26% |
PHR has the edge over HIMS on returns for 2026, with the stronger performance.